Moledina Malik, Patel Bhupendra C K, Malhotra Raman
Corneoplastic Unit, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.
Moran Eye Center, University of Utah, Salt Lake, UT, USA.
Semin Ophthalmol. 2025 Feb;40(2):97-106. doi: 10.1080/08820538.2024.2381772. Epub 2024 Jul 26.
Topical chloramphenicol is one of the most ubiquitous antibiotics used in ophthalmology and oculoplastic surgery globally. It shows broad-spectrum activity against a variety of different pathogenic organisms, is well tolerated on the ocular surface and displays excellent topical pharmacokinetics. Chloramphenicol has been available for purchase over the counter in the United Kingdom since 2005. Despite this, the largest health economy in the world, The United States has had a de-facto moratorium on its use for the past 30 years. In this review, we aim to evaluate topical chloramphenicol in ophthalmology and oculoplastic surgery and to determine whether its reputation within the US is warranted and justified.
We conducted a comprehensive literature review to evaluate the different facets of chloramphenicol, providing a detailed understanding of the drug, its historical context, the benefits and perceived risks, including safety concerns, and clinical perspectives of its use in clinical practice.
The mechanism of chloramphenicol, the context around which the drug's use in the US declined, and the drug's evidence base and safety data, including published case reports of serious adverse events, were analysed. The perceived benefits of the drug, particularly in light of antimicrobial resistance and its economic impact, were reviewed. Finally, perspectives on its use in clinical practice in ophthalmology and associated allied specialities were presented.
Chloramphenicol and its topical application have been misunderstood for many decades, particularly in the United States. Its demise across the Atlantic was due to an overzealous response to a dubious association with a weak evidence base. Numerous authors have since validated the safety profile of the and its safety has been borne out. The benefits of chloramphenicol, an effective broad-spectrum agent with a positive cost differential in the era of anti-microbial resistance and fiscal tightening, cannot be understated. Its likely effectiveness as a therapeutic topical agent in ophthalmic surgery makes it a valuable tool in the ophthalmic anti-microbial armoury. We would encourage the reinstatement of this valuable yet misunderstood drug as a first-line agent for simple ophthalmic infections.
局部用氯霉素是全球眼科和眼整形手术中使用最广泛的抗生素之一。它对多种不同的致病生物具有广谱活性,在眼表耐受性良好,并且具有出色的局部药代动力学特性。自2005年以来,氯霉素在英国可在柜台购买。尽管如此,世界上最大的卫生经济体美国在过去30年里实际上已暂停使用该药。在本综述中,我们旨在评估局部用氯霉素在眼科和眼整形手术中的应用,并确定其在美国的声誉是否合理。
我们进行了全面的文献综述,以评估氯霉素的不同方面,详细了解该药物、其历史背景、益处和感知到的风险(包括安全问题)以及其在临床实践中的使用的临床观点。
分析了氯霉素的作用机制、其在美国使用量下降的背景以及该药物的证据基础和安全数据,包括已发表的严重不良事件病例报告。回顾了该药物的感知益处,特别是鉴于抗菌耐药性及其经济影响。最后,介绍了其在眼科及相关附属专业临床实践中的使用观点。
几十年来,氯霉素及其局部应用一直被误解,尤其是在美国。它在大西洋彼岸的失宠是由于对与薄弱证据基础的可疑关联反应过度。此后,众多作者证实了其安全性,其安全性也得到了证实。氯霉素作为一种有效的广谱药物,在抗菌耐药性和财政紧缩时代具有积极的成本差异,其益处不可低估。它作为眼科手术中一种治疗性局部用药的可能有效性使其成为眼科抗菌药库中的一种有价值的工具。我们鼓励恢复使用这种有价值但被误解的药物,作为简单眼部感染的一线用药。